Bactiguard Holding AB (OSTO:BACTI B)

kr 35.3 -2.7 (-7.11%) Market Cap: 1.24 Bil Enterprise Value: 1.37 Bil PE Ratio: 0 PB Ratio: 4.06 GF Score: 60/100

Q3 2024 Bactiguard Holding AB Earnings Call Transcript
Oct 24, 2024

kr45 (+1.58%)

Earnings
Q2 2024 Bactiguard Holding AB Earnings Call Transcript
Jul 16, 2024

kr72 (+4.65%)

Earnings
Q4 2023 Bactiguard Holding AB Earnings Call Transcript
Feb 08, 2024

kr67.1 (-14.52%)

Earnings
Q2 2023 Bactiguard Holding AB Earnings Call Transcript
Jul 18, 2023

kr67.8 (-0.29%)

Earnings
Q1 2023 Bactiguard Holding AB Earnings Call Transcript
Apr 27, 2023

kr63.4 (-7.45%)

Earnings
Q4 2022 Bactiguard Holding AB Earnings Call Transcript
Feb 09, 2023

kr99.8 (-5.85%)

Earnings
Q3 2022 Bactiguard Holding AB Earnings Call Transcript
Oct 27, 2022

kr103.4 (-1.34%)

Earnings
Q2 2022 Bactiguard Holding AB Earnings Call Transcript
Jul 14, 2022

kr100.8 (-3.08%)

Earnings
Q1 2022 Bactiguard Holding AB Earnings Call Transcript
Apr 27, 2022

kr116.4 (-1.36%)

Earnings
Q4 2021 Bactiguard Holding AB Earnings Call Transcript
Feb 09, 2022

kr140 (+1.30%)

Earnings
Q3 2021 Bactiguard Holding AB Earnings Call Transcript
Oct 28, 2021

kr164.8 (+3.00%)

Earnings
Bactiguard Holding AB Pareto Securities' Healthcare Conference 2021 Transcript
Sep 02, 2021
Q2 2021 Bactiguard Holding AB Earnings Call Transcript
Jul 15, 2021

kr192 (+0.10%)

Earnings
Bactiguard Holding AB Nordic Mid Small Cap Seminar 2021 Transcript
Jun 02, 2021
Q1 2021 Bactiguard Holding AB Earnings Call Transcript
Apr 22, 2021

kr188 (-1.05%)

Earnings
Q3 2020 Bactiguard Holding AB Earnings Call Transcript
Nov 05, 2020

kr152.5 (-1.61%)

Earnings
Q2 2020 Bactiguard Holding AB Earnings Call Transcript
Aug 13, 2020

kr194.5 (+9.89%)

Earnings

Q1 2022 Bactiguard Holding AB Earnings Call Transcript

Apr 27, 2022 / 09:00AM GMT

Release Date Price: kr116.4 (-1.36%)

Transcript

Anders GÃ;ransson

Bactiguard Holding AB - CEO

¶ -

Welcome to the call to all our shareholders, investors, analysts, and others who have joined today. We will share our Q1 results as well as a deep dive into our expanding license business, with a focus on the two new agreements we have signed with Zimmer Biomet as well as Dentsply Sirona, leading companies in their fields within orthopedics and the dental area.

Let's go to page 2. In our last quarterly call, we presented a new focused growth strategy as well as new financial goals. Core to our strategy is our vision of keeping people safe from infections. We do so by fighting the infections to save lives, limit antimicrobial resistance, and save cost for the healthcare system by providing safe and effective technology.

We will today share how we are executing on our strategy with a clear focus of getting our technologies to patients.

If we go to page 3 in an overview of our Q1 results. We had a strong sales quarter, both in license revenue through our partnerships with leading global medtech companies, a total of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.